Journal of Clinical Endocrinology & Metabolism, Vol 80, 558-561, Copyright © 1995 by Endocrine Society

ARTICLES

Abnormal concentration of maternal serum activin-A in gestational diseases

F Petraglia, D De Vita, A Gallinelli, L Aguzzoli, AR Genazzani, R Romero and TK Woodruff
Department of Obstetrics and Gynecology, Universities of Modena, Italy.

Serum plasma activin-A is measurable in the maternal circulation of healthy pregnant women, increases in specimens collected during the third trimester of gestation, and is highest at parturition. Hormone abnormalities are known to be associated with preterm labor or diabetes in pregnancy. Therefore, in the present study serum activin-A levels in normal controls were compared to those in pregnant women with preterm labor or gestational diabetes. In some cases, values were obtained before and after insulin therapy. In other controls and patients with preterm labor, the activin-A concentration in cord serum was also studied. A newly developed two-site immunotest was used to determine activin-A levels. Subjects included normal controls (n = 7), who were sampled throughout gestation every 5 weeks; pregnant women at term (38- 40 weeks) not in labor (n = 22); pregnant women at term in spontaneous labor (< 3.0 cm dilated; n = 42); women in preterm labor (25-35 weeks; n = 38); and women with gestational diabetes (20-39 weeks; n = 9). In control women, serum activin-A levels increased from 4.8 +/- 5.5 micrograms/L (mean +/- SD) at 20 weeks to 25.4 +/- 27.8 micrograms/L at 40 weeks (P < 0.01), and values correlated with gestational age. Pregnant women in preterm labor had serum activin-A concentrations (89.04 +/- 173.31 micrograms/L) higher than those in normal controls (P < 0.01), and no significant correlation to gestational age was found in this group of pregnant women. Healthy women in labor showed serum activin-A concentrations higher than those in women at term but not in labor (P < 0.01). Diabetic patients had serum activin-A concentrations (52.39 +/- 23.32 micrograms/L) significantly higher than those in normal controls. In these patients, maternal serum activin-A concentrations significantly decreased to the range in healthy controls at the same gestational age after insulin therapy (9.48 +/- 3.82 micrograms/L). The present study shows that preterm labor is associated with increased concentrations of activin-A in the maternal circulation and cord serum. Hypersecretion of activin-A is also shown in same patients with gestation diabetes; this reverts to normal after insulin treatment.

This article has been cited by other articles:

				P. Ciarmela, E. Wiater, and W. Vale Activin-A in Myometrium: Characterization of the Actions on Myometrial Cells Endocrinology, May 1, 2008; 149(5): 2506 - 2516. [Abstract] [Full Text] [PDF]

				E.K. Moses, E. Fitzpatrick, K.A. Freed, T.D. Dyer, S. Forrest, K. Elliott, M.P. Johnson, J. Blangero, and S.P. Brennecke Objective prioritization of positional candidate genes at a quantitative trait locus for pre-eclampsia on 2q22 Mol. Hum. Reprod., August 1, 2006; 12(8): 505 - 512. [Abstract] [Full Text] [PDF]

				F. Debieve, L. Hinck, J.-M. Biard, P. Bernard, and C. Hubinont Activin receptor expression and induction of apoptosis in rat blastocysts in vitro Hum. Reprod., March 1, 2006; 21(3): 618 - 623. [Abstract] [Full Text] [PDF]

				M. P. Plevyak, G. M. Lambert-Messerlian, A. Farina, N. P. Groome, J. A. Canick, and H. M. Silver Concentrations of Serum Total Activin A and Inhibin A in Preterm and Term Labor Patients: A Cross-Sectional Study Reproductive Sciences, May 1, 2003; 10(4): 231 - 236. [Abstract] [PDF]

				C. Welt, Y. Sidis, H. Keutmann, and A. Schneyer Activins, Inhibins, and Follistatins: From Endocrinology to Signaling. A Paradigm for the New Millennium Experimental Biology and Medicine, October 1, 2002; 227(9): 724 - 752. [Abstract] [Full Text] [PDF]

				J. A. Keelan, R. L. Zhou, L. W. Evans, N. P. Groome, and M. D. Mitchell Regulation of Activin A, Inhibin A, and Follistatin Production in Human Amnion and Choriodecidual Explants by Inflammatory Mediators Reproductive Sciences, September 1, 2000; 7(5): 291 - 296. [Abstract] [PDF]

				W. A. GROBMAN and E. Y. WANG Serum Levels of Activin A and Inhibin A and the Subsequent Development of Preeclampsia Obstet. Gynecol., September 1, 2000; 96(3): 390 - 394. [Abstract] [Full Text] [PDF]

				E. R. Norwitz, J. N. Robinson, and J. R.G. Challis The Control of Labor N. Engl. J. Med., August 26, 1999; 341(9): 660 - 666. [Full Text] [PDF]

				A.E. O'Connor, J.R. McFarlane, S. Hayward, T. Yohkaichiya, N.P. Groome, and D.M. de Kretser Serum activin A and follistatin concentrations during human pregnancy: a cross-sectional and longitudinal study Hum. Reprod., March 1, 1999; 14(3): 827 - 832. [Abstract] [Full Text] [PDF]

				L. B. Draper, H. Chong, E. Wang, and T. K. Woodruff The Uterine Myometrium Is a Target for Increased Levels of Activin A during Pregnancy Endocrinology, July 1, 1997; 138(7): 3042 - 3046. [Abstract] [Full Text] [PDF]

				E. M. Wallace, S. C. Riley, J. A. Crossley, S. C. Ritoe, A. Horne, M. Shade, P. M. Ellis, D. A. Aitken, and N. P. Groome Dimeric Inhibins in Amniotic Fluid, Maternal Serum, and Fetal Serum in Human Pregnancy J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 218 - 222. [Abstract] [Full Text] [PDF]